Treatment and prognosis of patients with paraplegia or quadriplegia because of metastatic spinal cord compression in prostate cancer

Nagata, Michio; Ueda, Takeshi; Komiya, Akira; Suzuki, Hiroyoshi; Akakura, Koichiro; Ishihara, Misa; Tobe, Toyofusa; Ichikawa, Tomohiko; Igarashi, Tatsuo; Itô, Haruo

doi:10.1038/sj.pcan.4500641

Cited by 17 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found that paraplegia was associated with prostate cancer aggressivity, as corroborated by R M Jameson [35]. This paraplegia is due to metastatic spinal cord compression, which is considered a serious complication of prostate cancer that only occurs in aggressive forms of the disease [36]. We also identified factors that were associated with both aggressive disease and patients' outcomes (survival or death).…”

Section: Discussionsupporting

confidence: 71%

Prostate Cancer: Risk Factors and Outcome Indicators

Kamadjou¹,

Wadeu²,

Kuitche³

et al. 2022

View full text Add to dashboard Cite

Background: Prostate cancer, which is the second most frequent cancer diagnosis made in men, more commonly occurs in the elderly. This disease is often diagnosed late in resource-limited settings, which results in people having advanced forms of the disease and a poor prognosis. This study aimed to identify factors indicative of prostate cancer aggressivity and a poor prognosis in patients with prostate cancer at a single center in Douala, Cameroon.Methods: We performed a retrospective study from 2015 to 2020 at the Centre medico-chirugical d'urologie in Douala, Cameroon, in which we included 203 patients aged 41 years to 85 years who had prostate cancer diagnosed via histopathology after either prostate biopsyor laparoscopic prostatectomy. Epi-info 7 was used for data analysis and logistic regression analyses were performed to identify factors associated with prostate cancer aggressivity and patients' outcomes (survival or mortality). Results: The mean age of our study participants was 64.76 ± 7.48 years. Ten patients had a contributive family history of prostate cancer. The patients presented with lower urinary tract symptoms in 61.58% of cases. All patients had serum prostate-specific antigen (PSA) levels of >4 ng/ml, 100 patients were anemic, and 36 patients had aggressive forms of the disease. Eighty-eight patients had remarkable digital rectal examination (DRE) findings. The median prostate volume, as determined via transrectal ultrasonography (TRUS), was 59 [43 -80] ml. Fifty-nine patients had abnormal prostate echostructures, and 33 patients died during follow-up. The presence of paraplegia and the practice of professions requiring

show abstract

Section: Discussionsupporting

confidence: 71%

Prostate Cancer: Risk Factors and Outcome Indicators

Kamadjou¹,

Wadeu²,

Kuitche³

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The high relative frequency of hospitalizations for neoplasms in persons with SCI were mainly due to secondary malignant neoplasms of bone or bone marrow (192 hospitalizations) and unspecified parts of the nervous system (29 hospitalizations). It is likely that some of these diseases lead to non-traumatic SCI ( Nagata et al, 2003 , New et al, 2002 ) and were therefore hospitalizations for newly acquired SCI and not for the envisaged health maintaining. Similar reasoning applies to diseases of the nervous system in persons with SCI.…”

Section: Limitationsmentioning

confidence: 99%

Inpatient migration patterns in persons with spinal cord injury: A registry study with hospital discharge data

Ronca

Scheel‐Sailer

Koch

et al. 2016

SSM - Population Health

View full text Add to dashboard Cite

This study investigated and compared patient migration patterns of persons with spinal cord injury, the general population and persons with morbid obesity, rheumatic conditions and bowel disease, for secondary health conditions, across administrative boundaries in Switzerland. The effects of patient characteristics and health conditions on visiting hospitals outside the residential canton were examined using complete, nationwide, inpatient health records for the years 2010 and 2011. Patients with spinal cord injury were more likely to obtain treatment outside their residential canton as compared to all other conditions. Facilitators of patient migration in persons with spinal cord injury and the general hospital population were private or accidental health insurances covering costs. Barriers of patient migration in persons with spinal cord injury were old age, severe multimorbidity, financial coverage by basic health insurance, and minority language region.

show abstract

“…In all our paraplegic or tetraplegic patients, the neurological deficit was the complaint which led to the diagnosis of the metastatic prostate cancer. Nevertheless, pelvic limbs' paralysis may also supervene in metastatic prostate cancer patients while castration is ongoing [13]. Furthermore, the survival is insignificantly longer in patients with pretreatment paraplegia compared to patients in whom the paraplegia occurred during castration [13].…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, pelvic limbs' paralysis may also supervene in metastatic prostate cancer patients while castration is ongoing [13]. Furthermore, the survival is insignificantly longer in patients with pretreatment paraplegia compared to patients in whom the paraplegia occurred during castration [13].…”

Section: Discussionmentioning

confidence: 99%

Survival Rate and Factors Influencing It in Triptorelin-Castrated Metastatic Prostate Cancer Patients

Jean,

Gilvias,

Inès

et al. 2024

OJU

View full text Add to dashboard Cite

Background: Most newly diagnosed prostate cancers in Benin are metastatic diseases and patients are reluctant to undergo orchiectomy. Still, chemical androgen deprivation therapy is not always available and not every patient can afford it. Thus, it will be interesting to evaluate the results of that therapy in the country. Objective: To analyze the survival rate and factors influencing it in metastatic prostate cancer patients who underwent triptorelin-based androgen deprivation therapy at the former Military Teaching Hospital of Cotonou from January 1, 2012, to December 31, 2022. Patients and Method: Metastatic prostate cancer patients received intragluteal injections of triptorelin 11.25 mg every 3 months. We retrospectively collected follow-up data from the patients' medical records. By means of the software Stata TM version 15, we performed a descriptive analysis of qualitative data. We used Kaplan-Meir method to estimate the overall survival rate in the whole cohort and in specific subgroups of patients. We compared survival rates by using the log-rank test. Results: 68 metastatic prostate cancer patients aged 47 -86 years (mean = 69.9) with initial PSA ranging from 24.25 to 6334 ng/mL (mean = 666.1) started triptorelin-based castration. The tumor grade in 21 (33.3%), 14 (22.2%), 15 (23.8), 8 (12.7%), and 5 (7.9%) patients was respectively ISUP grade groups 5, 4, 3, 2, and 1. 15 (22.1%), 4 (5.9%), 2 (2.9%), 1 (1.5%), 11 (16.2%), and 7 (10.3%) patients respectively had hypertension, diabetes mellitus, peptic ulcer, asthma, unilateral or bilateral hydronephrosis, and paralysis. The mean nadir PSA level was 22.5 ng/mL (range: 0.01 -220.25). The mean time to nadir PSA level was 8.9 months (range: 3 -57). The overall survival rate was 42.6%. There was no significant survival difference between age groups (p = 0.475), relating to the presence of diabetes or hypertension (p = 0.

show abstract

Treatment and prognosis of patients with paraplegia or quadriplegia because of metastatic spinal cord compression in prostate cancer

Cited by 17 publications

References 20 publications

Prostate Cancer: Risk Factors and Outcome Indicators

Prostate Cancer: Risk Factors and Outcome Indicators

Inpatient migration patterns in persons with spinal cord injury: A registry study with hospital discharge data

Survival Rate and Factors Influencing It in Triptorelin-Castrated Metastatic Prostate Cancer Patients

Contact Info

Product

Resources

About